FDA Brief

Warning letters Drugs

FDA warning letter to

Thomas Brunner Hygiene GmbH

High riskIssued Jul 24Posted Aug 4Center for Drug Evaluation and Research (CDER)

Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

What happened

FDA found this by reviewing company records submitted after an August 12, 2025 request and by reviewing product labels and the https://syneo.us/ website in April 2026. The records showed no finished-batch assay testing, no process or cleaning validation, no adequate raw-material identity testing (including glycerin for diethylene glycol (DEG) and ethylene glycol (EG)), no water testing, and inadequate stability testing. The labels and website showed the syNeo products are intended as antiperspirant drugs, but they combine aluminum chlorohydrate and aluminum chloride, a combination not allowed by the OTC monograph.

What FDA found

  1. The firm did not test each finished drug batch for identity and strength of active ingredients before release.

    21 CFR 211.165(a)
  2. The firm did not establish adequate production controls or validate its manufacturing and cleaning processes.

    21 CFR 211.100(a) and 211.67(b)
  3. The firm did not adequately test incoming components and water, including identity testing of glycerin for DEG and EG.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The firm did not establish and follow an adequate stability testing program to support product expiry.

    21 CFR 211.166(a)
  5. The syNeo antiperspirants are unapproved new drugs because they combine aluminum chlorohydrate and aluminum chloride, which the OTC monograph does not permit together.

    FD&C Act section 505(a), 21 U.S.C. 355(a), and section 301(d), 21 U.S.C. 331(d)
  6. The syNeo antiperspirants are misbranded because they are nonprescription drugs that do not meet section 505G and lack an approved application.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)

What FDA wants

FDA asks the company to correct the CGMP and labeling violations, including testing reserve samples, assessing and testing for DEG/EG risk with results due within 30 calendar days, improving process and cleaning validation, and fixing stability and component/water testing. It also directs the firm to use a qualified consultant and provide corrective action plans.

Who should pay attention

  • distributors and retailers of syNeo antiperspirants
  • OTC drug brands using shared equipment or glycerin
  • firms relying on supplier certificates for raw-material identity

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk